Core Viewpoint - Mettler-Toledo reported quarterly earnings of $8.19 per share, exceeding the Zacks Consensus Estimate of $7.90, but down from $8.89 per share a year ago, indicating a 7.9% year-over-year decline in earnings [1][2] Financial Performance - The company achieved revenues of $883.74 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1%, but down from $925.95 million in the same quarter last year, reflecting a year-over-year revenue decline of 4.6% [2] - Mettler-Toledo has consistently surpassed consensus EPS estimates over the last four quarters, achieving an earnings surprise of 3.67% in the latest report [1][2] Stock Performance - Mettler-Toledo shares have declined approximately 12.5% since the beginning of the year, compared to a 5.3% decline in the S&P 500 [3] - The current Zacks Rank for Mettler-Toledo is 3 (Hold), indicating that the stock is expected to perform in line with the market in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $10.22, with expected revenues of $957.72 million, while the estimate for the current fiscal year is $42.51 on revenues of $3.91 billion [7] - The trend of estimate revisions for Mettler-Toledo is currently mixed, which may change following the latest earnings report [6] Industry Context - The Medical - Instruments industry, to which Mettler-Toledo belongs, is currently ranked in the top 23% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Exponent (EXPO) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.33%. A quarter ago, it was expected that this engineering and scientific consulting company would post earnings of $0.40 per share when it actually produced earnings of $0.46, delivering a surprise of 15%.Over the last ...

Company Performance - Asure Software Inc (ASUR) reported quarterly earnings of $0.19 per share, exceeding the Zacks Consensus Estimate of $0.18 per share, but down from $0.21 per share a year ago, representing an earnings surprise of 5.56% [1] - The company posted revenues of $34.85 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.67% and up from $31.65 million year-over-year [2] - Over the last four quarters, Asure Software has surpassed consensus EPS estimates just once and topped consensus revenue estimates only once [2] Stock Performance - Asure Software shares have increased approximately 8% since the beginning of the year, contrasting with the S&P 500's decline of 5.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.15 on revenues of $31.41 million, and for the current fiscal year, it is $0.89 on revenues of $135.09 million [7] Industry Outlook - The Internet - Delivery Services industry, to which Asure Software belongs, is currently ranked in the bottom 18% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Asure Software's stock performance [5]

分组1 - Kura Oncology reported a quarterly loss of $0.66 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.51, and compared to a loss of $0.59 per share a year ago, indicating an earnings surprise of -29.41% [1] - The company posted revenues of $14.11 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 88.19%, and this is a significant increase from zero revenues a year ago [2] - Kura Oncology shares have declined approximately 24.7% since the beginning of the year, contrasting with the S&P 500's decline of -5.3% [3] 分组2 - The earnings outlook for Kura Oncology is mixed, with the current consensus EPS estimate for the coming quarter at -$0.62 on revenues of $41.42 million, and for the current fiscal year at -$1.66 on revenues of $193.66 million [7] - The Medical - Biomedical and Genetics industry, to which Kura Oncology belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Core Insights - Alignment Healthcare reported a quarterly loss of $0.05 per share, better than the Zacks Consensus Estimate of a loss of $0.12, and an improvement from a loss of $0.25 per share a year ago, resulting in an earnings surprise of 58.33% [1] - The company achieved revenues of $926.93 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 4.21%, and showing significant growth from $628.6 million in the same quarter last year [2] - Alignment Healthcare's stock has increased approximately 57.5% year-to-date, contrasting with a -5.3% decline in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.05 on revenues of $940.64 million, and for the current fiscal year, it is -$0.37 on revenues of $3.75 billion [7] - The estimate revisions trend for Alignment Healthcare is favorable, leading to a Zacks Rank 2 (Buy), indicating expected outperformance in the near future [6] Industry Context - The Medical Services industry, to which Alignment Healthcare belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8]

Group 1 - Travere Therapeutics reported a quarterly loss of $0.47 per share, better than the Zacks Consensus Estimate of a loss of $0.55, and improved from a loss of $1.76 per share a year ago, representing an earnings surprise of 14.55% [1] - The company posted revenues of $81.73 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 3%, and showing significant growth from year-ago revenues of $41.37 million [2] - Travere shares have increased by approximately 19.5% since the beginning of the year, contrasting with the S&P 500's decline of -5.3% [3] Group 2 - The earnings outlook for Travere is uncertain, with current consensus EPS estimates at -$0.45 for the coming quarter and -$1.47 for the current fiscal year, alongside revenues of $83.04 million and $356.83 million respectively [7] - The Zacks Rank for Travere is currently 4 (Sell), indicating expectations of underperformance in the near future due to unfavorable estimate revisions [6] - The Medical - Biomedical and Genetics industry, to which Travere belongs, is currently in the top 32% of Zacks industries, suggesting a favorable environment for stocks within this sector [8]

Core Viewpoint - Hologic reported quarterly earnings of $1.03 per share, exceeding the Zacks Consensus Estimate of $1.02 per share, with revenues of $1.01 billion, surpassing expectations by 0.34% [1][2]. Financial Performance - The company has surpassed consensus EPS estimates three times over the last four quarters [2]. - Hologic's revenues for the quarter ended March 2025 were $1.01 billion, compared to $1.02 billion a year ago [2]. - The earnings surprise for the recent quarter was 0.98%, with the company expected to post earnings of $1.02 per share but actually reporting $1.03 [1][2]. Stock Performance - Hologic shares have declined approximately 19.3% since the beginning of the year, while the S&P 500 has decreased by 5.3% [3]. - The current Zacks Rank for Hologic is 3 (Hold), indicating expected performance in line with the market in the near future [6]. Future Outlook - The consensus EPS estimate for the upcoming quarter is $1.10 on revenues of $1.03 billion, and for the current fiscal year, it is $4.27 on revenues of $4.08 billion [7]. - The outlook for the industry, particularly the Medical - Instruments sector, is favorable, ranking in the top 23% of over 250 Zacks industries [8].

Group 1 - Cerus reported a quarterly loss of $0.04 per share, better than the Zacks Consensus Estimate of a loss of $0.05, representing an earnings surprise of 20% [1] - The company posted revenues of $43.24 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 2.95%, and up from $38.37 million a year ago [2] - Cerus has surpassed consensus EPS estimates three times over the last four quarters [2] Group 2 - The stock has underperformed, losing about 14.3% since the beginning of the year, compared to the S&P 500's decline of 5.3% [3] - The current consensus EPS estimate for the coming quarter is -$0.02 on revenues of $49.5 million, and -$0.10 on revenues of $198 million for the current fiscal year [7] - The Zacks Industry Rank for Medical - Products is in the bottom 28% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

Cullen/Frost Bankers (CFR) came out with quarterly earnings of $2.30 per share, beating the Zacks Consensus Estimate of $2.17 per share. This compares to earnings of $2.15 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.99%. A quarter ago, it was expected that this financial holding company would post earnings of $2.17 per share when it actually produced earnings of $2.36, delivering a surprise of 8.76%.Over the last four qu ...

Group 1 - Roblox reported a quarterly loss of $0.32 per share, better than the Zacks Consensus Estimate of a loss of $0.41, and an improvement from a loss of $0.43 per share a year ago, representing an earnings surprise of 21.95% [1] - The company achieved revenues of $1.21 billion for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 5.35%, and up from $923.76 million in the same quarter last year [2] - Roblox has surpassed consensus EPS estimates in all four of the last quarters and has topped consensus revenue estimates three times during the same period [2] Group 2 - The stock has increased approximately 15.9% since the beginning of the year, contrasting with a decline of -5.3% in the S&P 500 [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The trend for estimate revisions for Roblox is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Group 3 - The current consensus EPS estimate for the upcoming quarter is -$0.32 on revenues of $1.17 billion, and for the current fiscal year, it is -$1.47 on revenues of $5.29 billion [7] - The Gaming industry, to which Roblox belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] Group 4 - Flutter Entertainment, another company in the gaming industry, is expected to report quarterly earnings of $1.66 per share, reflecting a year-over-year change of +1560%, with revenues anticipated to be $3.7 billion, up 8.9% from the previous year [9][10]